Corrections: Neurological manifestations of autosomal dominant familial Alzheimer's disease: a comparison of the published literature with the Dominantly Inherited Alzheimer Network observational study (DIAN-OBS) (The Lancet Neurology (2016) 15(13) (1317–1325) (S1474442216302290) (10.1016/S1474-4422(16)30229-0));Neurological manifestations of autosomal dominant familial Alzheimer's disease: a comparison of the published literature with the Dominantly Inherited Alzheimer Network observational study (DIAN-OBS)

The Lancet Neurology

Volumn 15, Issue 13, 2016, Pages 1317-1325

  Tang, Mengxuan ^a   Ryman, Davis C ^a   McDade, Eric ^a   Jasielec, Mateusz S ^a   Buckles, Virginia D ^a   Cairns, Nigel J ^a   Fagan, Anne M ^a   Goate, Alison ^a   Marcus, Daniel S ^a   Xiong, Chengjie ^a   Allegri, Ricardo F ^b   Chhatwal, Jasmeer P ^c   Danek, Adrian ^d,e   Farlow, Martin R ^f   Fox, Nick C ^g   Ghetti, Bernardino ^f   Graff Radford, Neill R ^h   Laske, Christopher ⁱ   Martins, Ralph N ^j   Masters, Colin L ^k   Mayeux, Richard P ^l   Ringman, John M ^m   Rossor, Martin N ^g   Salloway, Stephen P ⁿ   Schofield, Peter R ^o   Morris, John C ^a   Bateman, Randall J ^a   more..

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Movement Disorders Section   (Argentina)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d UNIVERSITY OF MUNICH   (Germany)

^e GERMAN CENTER FOR NEURODEGENERATIVE DISEASES DZNE   (Germany)

^f INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY COLLEGE LONDON   (United Kingdom)

^h MAYO CLINIC   (United States)

ⁱ UNIVERSITY OF TÜBINGEN   (Germany)

^j EDITH COWAN UNIVERSITY   (Australia)

^k UNIVERSITY OF MELBOURNE   (Australia)

^l NewYork Presbyterian Hospital   (United States)

^m UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

ⁿ BROWN UNIVERSITY   (United States)

^o UNIVERSITY OF NEW SOUTH WALES   (Australia)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AGNOSIA; ALZHEIMER DISEASE; APHASIA; APRAXIA; ARTICLE; AUTOSOMAL DOMINANT DISORDER; BEHAVIOR CHANGE; BRAIN DISEASE; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CEREBELLAR ATAXIA; COHORT ANALYSIS; CORTICOBULBAR DEFICIT; DISEASE ASSOCIATION; FAMILIAL DISEASE; HALLUCINATION; HUMAN; MYOCLONUS; NEUROLOGIC DISEASE; NEUROLOGIC EXAMINATION; OBSERVATIONAL STUDY; ONSET AGE; PARKINSONISM; PERSONALITY DISORDER; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SEIZURE; SPASTICITY; SYSTEMATIC REVIEW; VISUAL AGNOSIA; COMPARATIVE STUDY; GENETICS; META ANALYSIS; PATHOPHYSIOLOGY;

ALZHEIMER DISEASE; HUMANS;

EID: 84994476570     PISSN: 14744422     EISSN: 14744465     Source Type: Journal    
DOI: 10.1016/S1474-4422(16)30327-1     Document Type: Erratum

References (31)

1. 1 Bateman, RJ, Aisen, PS, De Strooper, B, et al. Autosomal-dominant Alzheimer's disease: a review and proposal for the prevention of Alzheimer's disease. Alzheimer Res Ther, 3, 2011, 1.
2. 2 Storandt, M, Balota, DA, Aschenbrenner, AJ, Morris, JC, Clinical and psychological characteristics of the initial cohort of the Dominantly Inherited Alzheimer Network (DIAN). Neuropsychol 28 (2014), 19–29.
3. 3 Larner, AJ, Doran, M, Clinical phenotypic heterogeneity of Alzheimer's disease associated with mutations of the presenilin-1 gene. J Neurol 253 (2006), 139–158.
4. 4 Larner, AJ, Doran, M, Genotype-phenotype relationships of presenilin-1 mutations in Alzheimer's disease: an update. J Alzheimers Dis 17 (2009), 259–265.
5. 5 Ryan, NS, Rossor, MN, Correlating familial Alzheimer's disease gene mutations with clinical phenotype. Biomark Med 4 (2010), 99–112.
6. 6 Ryan, NS, Biessels, GJ, Kim, L, et al. Genetic determinants of white matter hyperintensities and amyloid angiopathy in familial Alzheimer's disease. Neurobiol Aging 36 (2015), 3140–3151.
7. 7 Morris, JC, Aisen, PS, Bateman, RJ, et al. Developing an international network for Alzheimer research: The Dominantly Inherited Alzheimer Network. Clin Investig 2 (2012), 975–984.
8. 8 Morris, JC, The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 43 (1993), 2412–2414.
9. 9 Talbot, C, Lendon, C, Craddock, N, Shears, S, Morris, JC, Goate, A, Protection against Alzheimer's disease with apoE epsilon 2. Lancet 343 (1994), 1432–1433.
10. 10 Cruchaga, C, Haller, G, Chakraverty, S, et al. Rare variants in APP, PSEN1 and PSEN2 increase risk for AD in late-onset Alzheimer's disease families. PLoS One, 7, 2012, e31039.
11. 11 Ryman, DC, Acosta-Baena, N, Aisen, PS, et al. Symptom onset in autosomal dominant Alzheimer disease: a systematic review and meta-analysis. Neurology 83 (2014), 253–260.
12. 12 Morris, JC, Weintraub, S, Chui, HC, et al. The Uniform Data Set (UDS): clinical and cognitive variables and descriptive data from Alzheimer Disease Centers. Alzheimer Dis Assoc Disord 20 (2006), 210–216.
13. 13 Ryan, NS, Nicholas, JM, Weston, PSJ, et al. Clinical phenotype and genetic associations in autosomal dominant familial Alzheimer's disease: a case series. Lancet Neurol, 2016 published online Oct 21. http://dx.doi.org/10.1016/S1474-4422(16)30193-4.
14. 14 Migliaccio, R, Agosta, F, Rascovsky, K, et al. Clinical syndromes associated with posterior atrophy: early age at onset AD spectrum. Neurology 73 (2009), 1571–1578.
15. 15 Lindquist, SG, Hasholt, L, Bahl, JM, et al. A novel presenilin 2 mutation (V393M) in early-onset dementia with profound language impairment. Eur J Neurol 15 (2008), 1135–1139.
16. 16 Sitek, EJ, Narozanska, E, Peplonska, B, et al. A patient with posterior cortical atrophy possesses a novel mutation in the presenilin 1 gene. PLoS One, 8, 2013, e61074.
17. 17 Barnes, J, Dickerson, BC, Frost, C, Jiskoot, LC, Wolk, D, van der Flier, WM, Alzheimer's disease first symptoms are age dependent: evidence from the NACC dataset. Alzheimer Dementia 11 (2015), 1349–1357.
18. 18 Murray, ME, Graff-Radford, NR, Ross, OA, Petersen, RC, Duara, R, Dickson, DW, Neuropathologically defined subtypes of Alzheimer's disease with distinct clinical characteristics: a retrospective study. Lancet Neurol 10 (2011), 785–796.
19. 19 Gomez-Isla, T, Growdon, WB, McNamara, MJ, et al. The impact of different presenilin 1 andpresenilin 2 mutations on amyloid deposition, neurofibrillary changes and neuronal loss in the familial Alzheimer's disease brain: evidence for other phenotype-modifying factors. Brain 122 (1999), 1709–1719.
20. 20 Friedman, D, Honig, LS, Scarmeas, N, Seizures and epilepsy in Alzheimer's disease. CNS Neurosci Ther 18 (2012), 285–294.
21. 21 Hauser, WA, Morris, ML, Heston, LL, Anderson, VE, Seizures and myoclonus in patients with Alzheimer's disease. Neurology 36 (1986), 1226–1230.
22. 22 Irizarry, MC, Jin, S, He, F, et al. Incidence of new-onset seizures in mild to moderate Alzheimer disease. Arch Neurolr 69 (2012), 368–372.
23. 23 Mendez, MF, Catanzaro, P, Doss, RC, Arguello, R, Frey, WH 2nd, Seizures in Alzheimer's disease: clinicopathologic study. J Geriatr Psychiatry Neurol 7 (1994), 230–233.
24. 24 Pandis, D, Scarmeas, N, Seizures in Alzheimer disease: clinical and epidemiological data. Epilepsy Curr 12 (2012), 184–187.
25. 25 Vossel, KA, Beagle, AJ, Rabinovici, GD, et al. Seizures and epileptiform activity in the early stages of Alzheimer disease. JAMA Neurol 70 (2013), 1158–1166.
26. 26 Palop, JJ, Mucke, L, Epilepsy and cognitive impairments in Alzheimer disease. Arch Neurol 66 (2009), 435–440.
27. 27 Mann, DM, Pickering-Brown, SM, Takeuchi, A, Iwatsubo, T, for the Members of the Familial Alzheimer's Disease Pathology study group. Amyloid angiopathy and variability in amyloid beta deposition is determined by mutation position in presenilin-1-linked Alzheimer's disease. Am J Pathol 158 (2001), 2165–2175.
28. 28 Farrer, LA, Cupples, LA, Haines, JL, et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA 278 (1997), 1349–1356.
29. 29 Lendon, CL, Martinez, A, Behrens, IM, et al. E280A PS-1 mutation causes Alzheimer's disease but age of onset is not modified by ApoE alleles. Hum Mut 10 (1997), 186–195.
30. 30 Pastor, P, Roe, CM, Villegas, A, et al. Apolipoprotein Eepsilon4 modifies Alzheimer's disease onset in an E280A PS1 kindred. Ann Neurol 54 (2003), 163–169.
31. 31 Van Broeckhoven, C, Backhovens, H, Cruts, M, et al. APOE genotype does not modulate age of onset in families with chromosome 14 encoded Alzheimer's disease. Neurosci Lett 169 (1994), 179–180.